We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.90
Bid: 2.80
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.20 (7.143%)
Open: 2.90
High: 3.00
Low: 2.84
Prev. Close: 2.90
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

10 Jan 2018 15:19

RNS Number : 5221B
Allergy Therapeutics PLC
10 January 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Allergy Therapeutics PLC

LEI: 213800PQ7AHK7KGVOE23

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Placing of Shares

3. Details of person subject to the notification obligationiv

Name

Invesco Ltd.

City and country of registered office (if applicable)

1555 Peachtree Street NE, Suite 1800,

Atlanta, GA 30309 United States

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09-01-2018

6. Date on which issuer notified (DD/MM/YYYY):

10-01-2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.81%

0

4.81%

594,117,768

Position of previous notification (if

applicable)

5.62%

0

5.62%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

 

GB00B02LCQ05

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

28,618,373

4.81%

SUBTOTAL 8. A

28,618,373

4.81%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Invesco Asset

Management Limited.

4.81%

0

4.81%

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

Invesco (UK) Ltd.

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

Place of completion

Henley-on-Thames

Date of completion

10-01-2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEASFEFFPPEFF
Date   Source Headline
13th May 20196:14 pmRNSHolding(s) in Company
13th May 20194:41 pmRNSSecond Price Monitoring Extn
13th May 20194:35 pmRNSPrice Monitoring Extension
7th May 20197:00 amRNSResearch Published on Adjuvant Systems
25th Apr 20197:00 amRNSRegulatory and Trading Update
18th Mar 20194:41 pmRNSSecond Price Monitoring Extn
18th Mar 20194:36 pmRNSPrice Monitoring Extension
18th Mar 201911:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Take an objective view
18th Mar 201911:05 amRNSSecond Price Monitoring Extn
18th Mar 201911:00 amRNSPrice Monitoring Extension
18th Mar 20199:05 amRNSSecond Price Monitoring Extn
18th Mar 20199:00 amRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSTop Line Phase III results from B301 trial
6th Mar 201912:10 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Strong operating performance driving market share
6th Mar 20197:00 amRNSInterim Results
17th Jan 20199:56 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share
16th Jan 20197:00 amRNSTrading Update & Notice of Results
29th Nov 20185:59 pmRNSHoldings in Company
27th Nov 20181:12 pmRNSResult of AGM
27th Nov 20187:00 amRNSAGM Trading Update
12th Nov 201812:00 pmRNSPresentation at Jefferies Healthcare Conference
8th Nov 20187:00 amRNSDirectorate Change
7th Nov 20186:06 pmRNSHoldings in Company
2nd Nov 20187:00 amRNSGrant of Awards under Long Term Incentive Plan
24th Oct 20181:25 pmRNSHoldings in Company
24th Oct 20187:00 amRNSDirector/PDMR Shareholding
23rd Oct 20185:29 pmRNSAnnual Report and Accounts
23rd Oct 20183:28 pmRNSHoldings in Company
27th Sep 20187:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth
26th Sep 20187:00 amRNSPreliminary Results
8th Aug 20187:00 amRNSNotice of Results
27th Jul 20185:26 pmRNSHolding(s) in Company
26th Jul 201812:02 pmRNSHolding(s) in Company
19th Jul 201810:19 amRNSResults of Placing and Subscription
19th Jul 20187:00 amRNSProposed placing & subscription to raise £10.6m
16th Jul 20188:53 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Jul 20189:40 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market
12th Jul 20187:00 amRNSTrading Update
25th Jun 20187:52 amRNSPositive data of Pollinex Quattro Grass vaccine
29th May 20187:00 amRNSPositive data with house-dust mite immunotherapy
21st May 201812:25 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration
21st May 20187:00 amRNSPositive top-line results from Grass Ph II study
14th May 20187:00 amRNSPublication of MCT Adjuvant Data
16th Mar 20183:38 pmRNSGrant of Awards under Long Term Incentive Plan
16th Mar 201812:53 pmRNSDirector/PDMR Shareholding
7th Mar 20189:30 amRNSHardman: Clinical development towards submission
7th Mar 20187:00 amRNSInterim Results
28th Feb 20187:00 amRNSPolyvac® Peanut CMO appointed
12th Feb 20187:00 amRNSCompletion of recruitment in PQ Grass Ph II trial
2nd Feb 20187:15 amRNSHardman Research: Growth in a tough market

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.